According to Genome Sequencing Project statistics (http://www. ncbi. nlm. nih.
gov/genomes/static/gpstat. html), as of February 16, 2012, complete gene sequences have …

Urine has become one of the most attractive biofluids in clinical proteomics as it can be
obtained non-invasively in large quantities and is stable compared with other biofluids. The …

Because of its availability, ease of collection, and correlation with physiology and pathology,
urine is an attractive source for clinical proteomics/peptidomics. However, the lack of …

No validated biomarkers exist for acute graft-versus-host disease (GVHD). We screened
plasma with antibody microarrays for 120 proteins in a discovery set of 42 patients who …

Clinical proteomics has yielded some early positive results—the identification of potential
disease biomarkers—indicating the promise for this analytical approach to improve the …

During the past decade, progress in basic immunology has been impressive. In parallel,
whereas our understanding of the pathophysiology of acute graft-versus-host disease …

Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow
transplantation, affects the skin, liver, and gastrointestinal tract. There are no plasma …

Capillary electrophoresis combined with mass spectrometry (CE‐MS) has been used for
several years for the investigation of proteins and peptides as biomarkers for diagnosis and …

A limitation of proteomic methods with respect to their clinical applicability is the lack of
possibilities to directly deduce the amount of a protein or peptide from a particular mass …

Sparked by the article from Lescuyer and colleagues in a recent issue, we aim here to
further encourage interest in and discussion of clinically relevant biomarker research. We …